ReviewNature reviews. Rheumatology2014
Persisting eicosanoid pathways in rheumatic diseases.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 84 citations in OpenAlex.
- Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis.Arthritis research & therapy · 2024Trial
- Reactivity of mammalian lipoxygenases (ALOX isoforms) with phospholipids, biomembranes and lipoproteins.Communications biology · 2026Article
- Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration.Science (New York, N.Y.) · 2026Article
- Pentagalloyl glucose Suppresses MSU Crystal-Induced Gout Inflammation and Arachidonic Acid Production In Vitro and In Vivo.Research square · 2026Article
- Elevated Plasma Monounsaturated Fatty Acids and Their Associations with Disease Activity, Adiposity, and Sex in Patients with Rheumatoid Arthritis: A Cross-Sectional Study.medRxiv : the preprint server for health sciences · 2026Article
- Pentagalloyl glucose suppresses MSU crystal-induced gout inflammation and arachidonic acid productionFrontiers in pharmacology · 2026Article
- Dietary supplementation of arachidonic acid promotes humoral immunity.EMBO molecular medicine · 2025Article
- Glycosaminoglycans in osteoarthritis cartilage promote inflammation by preferential activation of the lipoxygenase rather than the cyclooxygenase pathway.Advances in rheumatology (London, England) · 2025Article
- Multi-omics and network pharmacology reveal Huayu-Tongbi decoction reduced arthritis-related bone erosion.Chinese medicine · 2025Article
- Protective impact of circulating ω-3 PUFAs on sepsis susceptibility throughFrontiers in medicine · 2025Article
- Identification of key genes and long non‑coding RNA expression profiles in osteoporosis with rheumatoid arthritis based on bioinformatics analysis.BMC musculoskeletal disorders · 2024Article
- Synovial 5-Lipoxygenase-Derived Oxylipins Define a Lympho-Myeloid-Enriched Synovium.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Impacts of Omega-3 Fatty Acids, Natural Elixirs for Neuronal Health, on Brain Development and Functions.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Serum fatty acid profiles in systemic lupus erythematosus and patient reported outcomes: The Michigan Lupus Epidemiology & Surveillance (MILES) Program.Frontiers in immunology · 2024Article
- The Anti-Arthritic Activity of Diclofenac Lipid-Core Nanocapsules: Stereological Analysis Showing More Protection of Deep Joint Components.Molecules (Basel, Switzerland) · 2023Article
- Identification of polyunsaturated fatty acids as potential biomarkers of osteoarthritis after sodium hyaluronate and mesenchymal stem cell treatment through metabolomics.Frontiers in pharmacology · 2023Article
- Where traditional Chinese medicine meets Western medicine in the prevention of rheumatoid arthritis.Journal of internal medicine · 2022Review
- In Vitro and In Vivo Anti-Arthritic Potential ofMolecules (Basel, Switzerland) · 2022Article
- Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis.Experimental & molecular medicine · 2022Article
- Lipidomic Profiling in Synovial Tissue.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An unmet clinical need exists for early treatment of rheumatic diseases and improved treatment strategies that can better maintain remission with reduced ongoing subclinical inflammation and bone destruction. Eicosanoids form one of the most complex networks in the body controlling many physiological and pathophysiological processes, including inflammation, autoimmunity and cancer. Persisting eicosanoid pathways are thought to be involved in the development of rheumatic diseases, and targeting this pathway might enable improved treatment strategies. Several enzymes of the arachidonic acid cascade as well as eicosanoid receptors (all part of the eicosanoid pathway) are today well-recognized targets for anti-inflammatory drugs that can reduce symptoms of inflammation in rheumatic diseases. In this Review, we outline the evidence supporting pivotal roles of eicosanoid signalling in the pathogenesis of rheumatic diseases and discuss findings from studies in animals and humans. We focus first on rheumatoid arthritis and discuss the upregulation of the cyclooxygenase and lipoxygenase pathways as most data are available in this condition. Research into the roles of eicosanoids in other rheumatic diseases (osteoarthritis, idiopathic inflammatory myopathies, systemic lupus erythematosus and gout) is also progressing rapidly and is discussed. Finally, we summarize the prospects of targeting eicosanoid pathways as anti-inflammatory treatment strategies for patients with rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.